Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DTP Trial: Durvalumab with Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer
NCT03820141Phase 2Active, not recruiting
- Sponsor
- Houston Methodist Research Institute
- Start
- Jun 2020
- Primary completion
- Oct 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in breast cancer, sponsored by Houston Methodist Research Institute. Started Jun 2020; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03820141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03820141.